PatrickMckayBolandMD
Oncology • New Brunswick, NJGastrointestinal Cancer, Hematologic Oncology
Associate Professor of Oncology
Dr. Boland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
195 Little Albany St Ste 2701
New Brunswick, NJ 08901Phone+1 732-235-7615Fax+1 732-235-6797
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Boston University Medical CenterResidency, Internal Medicine, 2006 - 2009
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2006
Certifications & Licensure
NJ State Medical License 2019 - 2025
NY State Medical License 2013 - 2020
PA State Medical License 2010 - 2014
MA State Medical License 2009 - 2012- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer Start of enrollment: 2013 May 01
- Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer Start of enrollment: 2015 May 08
- Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2017 Mar 24
- Join now to see all
Publications & Presentations
PubMed
- TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.Patrick M Boland, Sarbajit Mukherjee, Iman Imanirad, Namrata Vijayvergia, Seth D Cohen
British Journal of Cancer. 2024-11-01 - 2 citationsA phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer.Patrick M Boland, John M L Ebos, Kristopher Attwood, Michalis Mastri, Christos Fountzilas
JNCI Cancer Spectrum. 2024-04-30 - Recurrence-free survival dynamics following adjuvant chemotherapy for resected colorectal cancer: A systematic review of randomized controlled trials.Emma Vail, Ankur P Choubey, H Richard Alexander, David A August, Abril Berry
Cancer Medicine. 2024-01-01
Press Mentions
Health Headlines: Cancer Cases in Younger Generations on the RiseAugust 14th, 2024- Rutgers Cancer Institute of New Jersey Experts Available to Discuss Colorectal Cancer Topics Through MarchMarch 1st, 2021
New Treatment Combination Improves Outcomes for Some Patients with Colorectal CancerJune 2nd, 2018- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
